Literature DB >> 10438795

Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

R A Tripp1, D Moore, L Jones, W Sullender, J Winter, L J Anderson.   

Abstract

BALB/c mice sensitized to vaccinia virus expressed G protein of respiratory syncytial virus (RSV) develop a Th2-type cytokine response and pulmonary eosinophilia when challenged with live RSV. In this study, BALB/c mice were immunized or challenged with an RSV mutant lacking the G and SH proteins or with DNA vaccines coding for RSV G or F protein. F or G protein DNA vaccines were capable of sensitizing for pulmonary eosinophilia. The absence of the G and/or SH protein in the infecting virus resulted in a consistent increase both in pulmonary natural killer cells and in gamma interferon and tumor necrosis factor expression, as well as, with primary infection, a variable increase in neutrophils and CD11b(+) cells. The development of pulmonary eosinophilia in formalin-inactivated RSV-vaccinated mice required the presence of the G and/or SH protein in the challenge virus. These data show that G and/or SH protein has a marked impact on the inflammatory and innate immune response to RSV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438795      PMCID: PMC104227     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Potential of attenuated respiratory syncytial virus vaccine for infants and children.

Authors:  R H Parrott; H W Kim; C D Brandt; R M Chanock
Journal:  Dev Biol Stand       Date:  1975

2.  Role of conserved glycosylation site unique to murine class I MHC in recognition by Ly-49 NK cell receptor.

Authors:  R H Lian; J D Freeman; D L Mager; F Takei
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

3.  IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness.

Authors:  T Hussell; U Khan; P Openshaw
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

4.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

Authors:  J Chin; R L Magoffin; L A Shearer; J H Schieble; E H Lennette
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine.

Authors:  R E Weibel; J Stokes; M B Leagus; C C Mascoli; M R Hilleman
Journal:  Am Rev Respir Dis       Date:  1966-09

Review 6.  Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus.

Authors:  K McIntosh; J M Fishaut
Journal:  Prog Med Virol       Date:  1980

7.  Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection.

Authors:  T Hussell; P J Openshaw
Journal:  J Gen Virol       Date:  1998-11       Impact factor: 3.891

8.  Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.

Authors:  L C Spender; T Hussell; P J Openshaw
Journal:  J Gen Virol       Date:  1998-07       Impact factor: 3.891

9.  Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice.

Authors:  G W Wertz; E J Stott; K K Young; K Anderson; L A Ball
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

10.  Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.

Authors:  R A Tripp; L J Anderson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  65 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

Review 3.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.

Authors:  R A Tripp; D Moore; J Winter; L J Anderson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

8.  Bioconjugated nanoparticle detection of respiratory syncytial virus infection.

Authors:  Ralph A Tripp; Rene Alvarez; Blake Anderson; Les Jones; Craig Weeks; Wei Chen
Journal:  Int J Nanomedicine       Date:  2007

9.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

10.  Human metapneumovirus establishes persistent infection in the lungs of mice and is reactivated by glucocorticoid treatment.

Authors:  Yuru Liu; Debra L Haas; Spencer Poore; Sanjin Isakovic; Michelle Gahan; Suresh Mahalingam; Zhen F Fu; Ralph A Tripp
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.